2021
Analysis of Sociodemographic, Clinical, and Genomic Factors Associated With Breast Cancer Mortality in the Linked Surveillance, Epidemiology, and End Results and Medicare Database
Robinson TJ, Wilson LE, Marcom PK, Troester M, Lynch CF, Hernandez BY, Parrilla E, Brauer HA, Dinan MA. Analysis of Sociodemographic, Clinical, and Genomic Factors Associated With Breast Cancer Mortality in the Linked Surveillance, Epidemiology, and End Results and Medicare Database. JAMA Network Open 2021, 4: e2131020. PMID: 34714340, PMCID: PMC8556625, DOI: 10.1001/jamanetworkopen.2021.31020.Peer-Reviewed Original ResearchConceptsResidual tissue repositoryBreast cancer outcomesSEER-Medicare dataCancer outcomesCox proportional hazards regression modelHealth servicesEstrogen receptor-positive invasive breast cancerSymptomatic detectionBreast cancer-specific survivalPopulation-based cohort studyEstrogen receptor-positive tumorsProportional hazards regression modelsExploratory genomic analysisSEER-Medicare cohortCancer-specific survivalSocioeconomic statusHigh-grade diseaseInvasive breast cancerReceptor-positive tumorsSubset of womenBreast cancer mortalityAdvanced disease stageHazards regression modelsClaims-based algorithmGrowth factor β activation
2020
Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma diagnosed between 2008 and 2012
Dinan MA, Georgieva MV, Li Y, Zhang T, Harrison M, Shenolikar R, Scales CD. Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma diagnosed between 2008 and 2012. Journal Of Geriatric Oncology 2020, 12: 298-304. PMID: 32912737, DOI: 10.1016/j.jgo.2020.08.005.Peer-Reviewed Original ResearchConceptsMetastatic urothelial carcinomaSecond-line chemotherapyUrothelial carcinomaOlder patientsSystemic therapyTreatment optionsMedicare patientsReal-world treatment patternsGrade IV diseaseAdvanced urothelial carcinomaSecond-line treatmentPoor oncologic outcomesYear of diagnosisUpper urinary tractLimited treatment optionsAcademic cancer centerSEER-Medicare dataForm of chemotherapyNon-academic centersDoublet chemotherapyPlatinum doubletsNeoadjuvant chemotherapyLine therapyOncologic outcomesRenal diseaseAssociation of 21-Gene Assay (OncotypeDX) Testing and Receipt of Chemotherapy in the Medicare Breast Cancer Patient Population Following Initial Adoption
Dinan MA, Wilson LE, Reed SD, Griggs JJ, Norton EC. Association of 21-Gene Assay (OncotypeDX) Testing and Receipt of Chemotherapy in the Medicare Breast Cancer Patient Population Following Initial Adoption. Clinical Breast Cancer 2020, 20: 487-494.e1. PMID: 32653473, DOI: 10.1016/j.clbc.2020.05.010.Peer-Reviewed Original Research
2019
Simulated Costs of the ASCO Patient-Centered Oncology Payment Model in Medicare Beneficiaries With Newly Diagnosed Advanced Ovarian Cancer.
Moss HA, Havrilesky LJ, Wang FF, Georgieva MV, Hendrix LH, Dinan MA. Simulated Costs of the ASCO Patient-Centered Oncology Payment Model in Medicare Beneficiaries With Newly Diagnosed Advanced Ovarian Cancer. JCO Oncology Practice 2019, 15: e1018-e1027. PMID: 31613721, PMCID: PMC10445789, DOI: 10.1200/jop.19.00026.Peer-Reviewed Original ResearchConceptsAdvanced ovarian cancerOvarian cancerAlternative payment modelsNeoadjuvant chemotherapy patientsEmergency department visitsSEER-Medicare dataMean total costOutpatient emergency department visitsPayment modelsHealth care servicesCost-efficient careAvoidable spendingNeoadjuvant chemotherapyReal-world practiceDepartment visitsChemotherapy patientsCancer careMedicare beneficiariesHospitalizationCare servicesPatientsService MedicareChemotherapySurgeryPotential cost savingsChemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011.
Dinan MA, Wilson LE, Reed SD. Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011. Journal Of The National Comprehensive Cancer Network 2019, 17: 245-254. PMID: 30865923, DOI: 10.6004/jnccn.2018.7097.Peer-Reviewed Original ResearchConceptsLow-risk diseaseHigh-risk patientsHigh-risk diseaseRS testingMedicare beneficiariesPrimary analysisEstrogen receptor-positive breast cancerReceptor-positive breast cancerLower chemotherapy useIntermediate-risk diseaseIntermediate-risk patientsRetrospective cohort studyGenomic testingSEER-Medicare dataChemotherapy useCohort studyMultivariable analysisBreast cancerChemotherapy costsLow overall useMAIN OUTCOMEMedicare populationPatientsHigher overall costsDisease
2018
Initial Adoption of Recombinant Human Thyroid-Stimulating Hormone Following Thyroidectomy in the Medicare Thyroid Cancer Patient Population
Dinan MA, Li Y, Reed SD, Sosa JA. Initial Adoption of Recombinant Human Thyroid-Stimulating Hormone Following Thyroidectomy in the Medicare Thyroid Cancer Patient Population. Endocrine Practice 2018, 25: 31-42. PMID: 30383499, DOI: 10.4158/ep-2018-0253.Peer-Reviewed Original ResearchConceptsRecombinant human thyroid-stimulating hormoneHuman thyroid-stimulating hormoneThyroid-stimulating hormoneMultivariable analysisPatient populationUse of rhTSHLower inpatient costsMean outpatient costsDistant metastatic diseaseDifferentiated thyroid cancerEmergency department visitsRadioactive iodine administrationCancer patient populationSEER-Medicare dataCostly hospital staysTotal inpatient daysHealthcare Common Procedure Coding SystemTotal Medicare paymentsNumber of outpatientsMedicare patient populationPositron emission tomographySimilar overall costsRAI administrationHospital stayMultiple comorbiditiesAdvanced imaging and hospice use in end-of-life cancer care
Dinan MA, Curtis LH, Setoguchi S, Cheung WY. Advanced imaging and hospice use in end-of-life cancer care. Supportive Care In Cancer 2018, 26: 3619-3625. PMID: 29728843, DOI: 10.1007/s00520-018-4223-0.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBlack or African AmericanBreast NeoplasmsColorectal NeoplasmsComorbidityDiagnostic ImagingFemaleHospice CareHospicesHumansLung NeoplasmsMaleMedicareMiddle AgedNeoplasmsOutcome Assessment, Health CareProstatic NeoplasmsReferral and ConsultationRetrospective StudiesSEER ProgramTerminal CareUnited StatesConceptsHospital referral regionsHospice enrollmentComputerized tomographyHospice useLife careReferral regionsAdvanced imagingPopulation-based retrospective studyHigh rateLate hospice enrollmentLife cancer careMultivariable logistic regressionSEER-Medicare dataMagnetic resonance imagingPositron emission tomographyEnd of lifeGreater comorbidityReal-world practiceAggressive endBlack patientsMultivariable analysisRetrospective studyResultsA totalStudy criteriaCancer care
2013
Longitudinal trends in costs for palliative radiation for metastatic prostate cancer.
Robinson T, Dinan M, Li Y, Lee R, Reed S. Longitudinal trends in costs for palliative radiation for metastatic prostate cancer. Journal Of Clinical Oncology 2013, 31: 6554-6554. DOI: 10.1200/jco.2013.31.15_suppl.6554.Peer-Reviewed Original ResearchPalliative radiation therapyMetastatic prostate cancerProstate cancerRadiation therapyBony metastasesInclusion criteriaOutpatient facilitiesMedicare paymentsDistant metastatic diseaseTime of diagnosisPalliative radiation treatmentSEER-Medicare dataTreatment claimsStudy inclusion criteriaProstate cancer metastasisHealth care costsTotal Medicare paymentsAverage Medicare paymentsHealth care expendituresCarrier claimsPalliative radiationMetastatic diseasePalliative treatmentMedian ageMedian time